Scale-Up Crystallization of 1,1-Cyclohexanediacetic Acid Monoamide in Ethanol-Water

Solubility Anomalies of 1,1-Cyclohexanediacetic Acid Monoamide in Ethanol-Water Mixtures: From Lab to Pilot Scale

When scaling the synthesis of 1,1-cyclohexanediacetic acid monoamide—also known as 3-3-Pentamethylene glutaramic acid or 1-1-Cyclohexane diacetic acid monoamide—process engineers often encounter unexpected solubility behavior in ethanol-water systems. At bench scale, a 70:30 ethanol-water ratio may yield clean crystals, but in a 500 L reactor, the same ratio can lead to sudden precipitation or oiling out. This is not a flaw in the chemistry; it is a consequence of mixing dynamics and localized supersaturation. Our field experience shows that the monoamide exhibits a steep solubility curve between 40 °C and 10 °C, with a tendency to form metastable zones that are easily disturbed by agitation patterns. For a gabapentin intermediate of this type, industrial purity demands precise control over these anomalies to avoid butyrolactam impurities, which can carry through to the final API. We recommend starting with a solvent ratio closer to 60:40 ethanol-water for pilot batches, then adjusting based on in-situ particle size analysis. This approach mitigates the risk of uncontrolled nucleation and ensures a consistent crystal habit.

One non-standard parameter we have observed is the impact of trace water content on the monoamide's melting point depression. In ethanol-water systems, even a 2% variation in water content can shift the dissolution endpoint by 5–8 °C, leading to premature crystallization on cooling. This is particularly critical when sourcing material from different global manufacturers, where residual solvents may vary. For a deeper dive into purity considerations, see our article on sourcing 1,1-cyclohexanediacetic acid monoamide and controlling butyrolactam impurities. Additionally, our German-language resource Beschaffung Von 1,1-Cyclohexandiessigsäuremonoamid: Reinheitsgrade provides further insights into purity grades.

Controlling Crystallization Kinetics: Cooling Ramp Protocols to Prevent Rapid Nucleation and Filter Blinding

The crystallization of 1,1-cyclohexanediacetic acid monoamide is notoriously sensitive to cooling rate. In our kilo lab and pilot plant campaigns, we have documented that cooling faster than 0.3 °C/min between 35 °C and 15 °C almost invariably triggers secondary nucleation, producing a bimodal particle size distribution that blinds filters and traps mother liquor. The result is a product with elevated residual solvents and a higher risk of butyrolactam formation during subsequent drying. To achieve a pharmaceutical-grade monoamide suitable as a gabapentin intermediate, we employ a stepped cooling protocol: an initial linear ramp at 0.2 °C/min from 45 °C to 30 °C, a 1-hour hold at 30 °C to allow crystal growth, and then a slower 0.1 °C/min ramp to 5 °C. This protocol promotes the growth of large, well-faceted crystals that filter and wash efficiently.

Below is a step-by-step troubleshooting list for when crystallization deviates from the expected profile:

• Step 1: Check for oiling out. If the solution becomes turbid without distinct crystals, immediately reheat to 50 °C and add 5% v/v ethanol to shift the solvent composition. Seed with 0.5 wt% micronized monoamide at 40 °C.
• Step 2: Assess nucleation lag. If no crystals appear after 2 hours at the target nucleation temperature, scratch the vessel wall or apply brief ultrasonication. Avoid excessive shear, which can generate fines.
• Step 3: Diagnose filter blinding. If filtration time exceeds 30 minutes for a 10 kg batch, the crystal size distribution is likely too broad. Re-dissolve the cake in 60:40 ethanol-water at 50 °C and repeat the cooling protocol with a 0.05 °C/min ramp below 25 °C.
• Step 4: Mitigate agglomeration. If the dry product forms hard lumps, introduce a wet-milling step after filtration using a cone mill with a 1 mm screen. This breaks up aggregates without generating excessive fines.

For process engineers evaluating a drop-in replacement, our monoamide matches the crystallization behavior of leading competitors when these protocols are followed. The key is to treat the cooling ramp as a critical process parameter, not a simple unit operation.

Anti-Caking and Isolation Strategies for High-Purity 1,1-Cyclohexanediacetic Acid Monoamide at Scale

After crystallization, the isolation and drying of 1,1-cyclohexanediacetic acid monoamide present their own challenges. The product has a tendency to cake during storage, especially if residual moisture exceeds 0.5%. This caking is not merely a handling nuisance; it can lead to localized hydrolysis, generating butyrolactam and compromising the quality of the gabapentin intermediate. In our GMP facility, we have implemented a two-stage drying process: initial deliquoring under nitrogen pressure (0.5 bar) followed by vacuum drying at 40 °C with a slow nitrogen bleed. The nitrogen bleed helps sweep away ethanol vapors and prevents condensation in the vacuum line. We also add 0.1% w/w of a pharmaceutical-grade anti-caking agent, such as colloidal silicon dioxide, during the final blending step. This is particularly important for bulk shipments in 25 kg fiber drums, where compaction during transport can otherwise lead to solid block formation.

Another field observation concerns the monoamide's behavior at sub-zero temperatures. During winter shipments, we have noted that the product can undergo a slight amorphous-to-crystalline transition if exposed to temperatures below -10 °C for extended periods. This does not affect chemical purity but can alter the powder flowability. To mitigate this, we recommend storing the material at 15–25 °C and avoiding temperature cycling. Our logistics team ensures that all shipments are in climate-controlled containers when necessary. For a reliable supply of this critical intermediate, visit our product page: 1,1-cyclohexanediacetic acid monoamide for gabapentin synthesis.

Drop-in Replacement Qualification: Matching Competitor Performance with NINGBO INNO PHARMCHEM's Monoamide

For procurement managers and R&D leads, qualifying a new source of 1,1-cyclohexanediacetic acid monoamide can be a lengthy process. Our product is designed as a seamless drop-in replacement for existing suppliers, with identical key parameters: appearance (white crystalline powder), assay (≥99.0% by HPLC), melting point (143–146 °C), and residual solvents (ethanol <0.5%, water <0.5%). In side-by-side gabapentin synthesis trials, our monoamide yielded the same conversion and impurity profile as the leading brand, with no adjustments to reaction conditions. The only parameter that may require slight optimization is the initial dissolution time in ethanol-water, which can vary by 5–10 minutes depending on the particle size distribution. We provide a batch-specific certificate of analysis (COA) with every shipment, detailing these parameters. Please refer to the batch-specific COA for exact numerical specifications.

One edge case we have encountered is the presence of a faint yellow tint in some batches when dissolved in methanol. This is due to trace levels of an oxidized byproduct that forms if the drying temperature exceeds 50 °C. Our strict temperature controls during drying eliminate this issue, ensuring a colorless solution. This level of attention to detail is what makes our monoamide suitable for the most demanding pharmaceutical applications.

Frequently Asked Questions

What is the optimal ethanol-water ratio for recrystallizing 1,1-cyclohexanediacetic acid monoamide?

For most applications, a 60:40 v/v ethanol-water mixture provides the best balance of solubility and crystal yield. At 50 °C, the solubility is approximately 15 g/100 mL, dropping to 2 g/100 mL at 5 °C. Adjust the ratio if oiling out occurs; increasing ethanol content can help maintain a single liquid phase.

How can I prevent sudden precipitation during cooling?

Sudden precipitation is usually caused by too rapid cooling or insufficient seeding. Implement a controlled cooling ramp (0.2 °C/min or slower) and seed with 0.5–1.0 wt% of micronized monoamide at 5 °C above the expected cloud point. Ensure the seed crystals are well dispersed to avoid localized nucleation.

What causes filter cake compaction and how can it be avoided?

Compaction occurs when a wide particle size distribution allows fines to fill the voids between larger crystals. Use the stepped cooling protocol described above to narrow the distribution. If compaction persists, consider a pressure filtration system with a slow initial pressure ramp (0.1 bar/min) to build a permeable cake.

Does the monoamide form hydrates or solvates that affect drying?

We have not observed stable hydrate formation, but the product can retain ethanol in the crystal lattice if crystallized from pure ethanol. The ethanol-water mixture minimizes this risk. Always dry at ≤40 °C under vacuum to avoid thermal degradation.

Can I use this monoamide directly in gabapentin synthesis without further purification?

Yes, our product typically meets the purity requirements for direct use. However, we recommend checking the COA for butyrolactam content (<0.1%) and performing a small-scale trial to confirm compatibility with your specific process.

Sourcing and Technical Support

Securing a consistent supply of high-purity 1,1-cyclohexanediacetic acid monoamide is critical for uninterrupted gabapentin production. At NINGBO INNO PHARMCHEM, we combine deep process knowledge with robust manufacturing capabilities to deliver a product that meets the most stringent pharmaceutical standards. Our technical team is available to support scale-up trials, troubleshoot crystallization issues, and provide batch-specific documentation. Ready to optimize your supply chain? Reach out to our logistics team today for comprehensive specifications and tonnage availability.